 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Veracyte, Inc. Nasdaq: VCYT announced today that new data relating to the Prosigna Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology ESMO Breast Cancer Virtual Congress 2021 taking place May 5-8. New data accepted for presentation at this years ESMO Breast Cancer Congress provide further evidence for the importance of genomic testing in breast cancer, particularly to help physicians and patients 